Fraser Finance

The Landbanking Group is a private company focused on enhancing the investment in natural capital through an eco-tech platform. It unites scientists, builders, technology experts, and investors to facilitate payments and investments that support environmental sustainability. The platform offers account documents and trade certificates that verify ecosystem outcomes, thereby creating market access in various natural markets. This innovative approach enables businesses and investors to establish natural capital accounts, fostering a more sustainable and responsible approach to environmental resources.

Therapixel develops and commercializes AI-based software for breast cancer detection and characterization

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

Incision is a developer of a medical education platform built to offer a standardized method of how to perform a procedure in practical steps and sub-steps.

Spearad runs a multi format platform for Addressable TV advertising. Our platform helps media owners to monetize content for all available screens. Spearad changes the way advertising is sold, delivered and measured in the new era of personally-targeted and IP based TV. Our technology allows all media players in the television, OTT/VOD and Audio business to fully benefit from the advantages of digital advertising while still maintaining the specifics of audio and television. The company was founded by industry leaders ensuring maximum market acceptance and high standing technological expertise. Spearad is operating worldwide and currently has subsidiaries in Germany, UK and the US.

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and previously known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. The platform enables healthcare providers to unify clinical and administrative workflows, automate tasks, and deliver measurable care, addressing the underlying systems that drive healthcare transformation. Lumeon's clientele includes some of Europe's leading healthcare providers, such as BUPA and Nuffield Health, reflecting its position as a key player in the market. The company employs over 90 professionals dedicated to enhancing patient care through effective management and analysis of healthcare pathways.

Tessian Limited is a company that specializes in email security software designed to mitigate risks associated with human error and data loss. Founded in 2013 and headquartered in London, the company offers advanced solutions that leverage machine learning and artificial intelligence. Key products include CheckRecipient Guardian, which alerts users in real-time if emails are being sent to unintended recipients, and CheckRecipient RuleBuilder, which allows organizations to easily create and enforce email communication policies. The platform analyzes email networks to prevent sensitive information from being misdirected, thereby protecting clients in various sectors, including legal services, healthcare, investment banking, and technology. Tessian aims to enhance security while ensuring minimal disruption to employees' workflows, empowering them to work efficiently without compromising data integrity.

Clinical Genomics is a privately held biotechnology company developing innovative products for colorectal cancer diagnosis and monitoring. With a broad intellectual property portfolio including more than 20 issued and pending patents, Clinical Genomics has developed and validated a sensitive and specific blood test for colorectal cancer recurrence monitoring that will be launched in the U.S. in 2016. This 2-gene test, which is based on methylated DNA from two genes, BCAT1 and IKZF1, is currently known by its project name GEMINI.

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and previously known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. The platform enables healthcare providers to unify clinical and administrative workflows, automate tasks, and deliver measurable care, addressing the underlying systems that drive healthcare transformation. Lumeon's clientele includes some of Europe's leading healthcare providers, such as BUPA and Nuffield Health, reflecting its position as a key player in the market. The company employs over 90 professionals dedicated to enhancing patient care through effective management and analysis of healthcare pathways.

ExThera Medical Corporation is a medical device company based in Martinez, California, with an additional office in Stockholm, Sweden. Founded in 2007, the company focuses on addressing unmet clinical needs in the treatment of bloodstream infections and pathogen reduction in blood banking. Its flagship product, the Seraph Microbind Affinity Blood Filter, is designed to capture and remove a wide range of pathogens, including normal and drug-resistant bacteria, viruses, toxins, and pro-inflammatory cytokines from human blood. The device utilizes the affinity of bacteria for immobilized heparin, a naturally occurring anticoagulant, to lower pathogen concentration in the bloodstream. This innovative approach serves as an adjunct to conventional anti-infective therapies, potentially reducing the load and duration of infections and helping patients recover by supporting their immune systems. ExThera Medical's solutions aim to improve clinical outcomes for patients suffering from blood-borne diseases, including viremia and bacteremia, and enhance the safety of banked human blood.

Tessian Limited is a company that specializes in email security software designed to mitigate risks associated with human error and data loss. Founded in 2013 and headquartered in London, the company offers advanced solutions that leverage machine learning and artificial intelligence. Key products include CheckRecipient Guardian, which alerts users in real-time if emails are being sent to unintended recipients, and CheckRecipient RuleBuilder, which allows organizations to easily create and enforce email communication policies. The platform analyzes email networks to prevent sensitive information from being misdirected, thereby protecting clients in various sectors, including legal services, healthcare, investment banking, and technology. Tessian aims to enhance security while ensuring minimal disruption to employees' workflows, empowering them to work efficiently without compromising data integrity.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and previously known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. The platform enables healthcare providers to unify clinical and administrative workflows, automate tasks, and deliver measurable care, addressing the underlying systems that drive healthcare transformation. Lumeon's clientele includes some of Europe's leading healthcare providers, such as BUPA and Nuffield Health, reflecting its position as a key player in the market. The company employs over 90 professionals dedicated to enhancing patient care through effective management and analysis of healthcare pathways.

F2G Ltd is a biotechnology company focused on developing innovative therapies for serious fungal infections. Founded in 1998 and based in Manchester, United Kingdom, F2G primarily works on its F3 series of anti-mold compounds, specifically targeting antifungal agents against Aspergillus and other filamentous molds. Utilizing proprietary genomics technology known as MycoBank, the company identifies essential gene targets in fungi, which informs its drug development process. F2G has diversified its approach to include chemistry-driven discovery, leveraging a strong development team to advance its patented compounds. The company's efforts aim to address difficult-to-treat fungal pathogens that pose significant mortality risks, particularly for immunocompromised patients, thereby enhancing treatment options in the pharmaceutical industry.

Pole Star, founded in 2002 and based in the United States and in France, is the pioneer and world leader in indoor location. Pole Star’s mission is to deliver high performance and complete range of indoor location services for venue owners and mobile solution providers covering over 100 million square feet of indoor areas worldwide.